AcousticaBio

2 known investors

Acoustica.bio develops acoustophoretic technology and microgel suspension formulations that concentrate biologic drugs (such as monoclonal antibodies) to ultra-high concentrations exceeding 500 mg/mL for small-volume subcutaneous injection. It serves drug developers, aiming to convert hospital-based intravenous therapies into patient-friendly at-home injections in the biotech/drug delivery space.